London-based firm Nothing to release its Phone (2)
by IANS | Updated May 03, 2023
London-based consumer electronics company Nothing on Wednesday announced that the company will be releasing the Phone (2) this British summer.
The company said that the Nothing Phone (2) will be powered by Snapdragon's 8 Series processor and will be a more "premium" offering.
Moreover, it added that the second smartphone will also be available to purchase in the US for the first time.
Earlier, Manu Sharma, Vice President and General Manager, Nothing India, told IANS that they have learnt their lessons with the first smartphone and when they launch their second offering in India soon, it will be an industry-leading device.
"On Flipkart, we now have a rating of 4.4 for Nothing Phone (1) from an earlier 4.2 rating after improving user experience. When we launched Android 13 on Phone (1), the users' response was fantastic. We would carry our learnings to Phone (2) which will be an industry-first with our iconic design philosophy," Sharma elaborated.
"We now have a presence in 2,000 offline stores in India. We are likely to foray into launching our own retail store in India next year as we expand product portfolio," he added.
The company's first product, Ear (1), was received well. Following its success, the company's smartphone product Phone (1) was launched in July 2022.
- Optical Illusion Brain Test: If you have Sharp Eyes Find the Number 442 in 20 Secs
- London-based firm Nothing to release its Phone (2)
- Covid will continue to cause mini-waves, not become seasonal yet: Scientists
- Hackers offering crypto accounts for as low as $30 on darknet
- Reddit's new feature to allow users to share its content on other platforms
- Surgical masks can help kids fight respiratory infections: Study
- LinkedIn's new AI feature to write messages to hiring team
- Microsoft introduces Xbox Game Pass' new Friend Referral programme
- Disbursed over Rs 31 cr in claims to delivery partners in FY22-23: Swiggy
- India emerging as favourable destination for clinical trials: Report